GAMUNEX-C
The FDA has documented the indications for GAMUNEX-C to include the treatment of primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
This affects the manufacturer of GAMUNEX-C and stakeholders involved in the management of plasma-derived biologics, including regulatory and clinical operations functions.
The source establishes the specific scope of approved clinical use for this biologic. For regulatory professionals, this defines the boundaries for marketing claims and required safety reporting parameters. This clarity is essential for maintaining compliance with the FDA-approved labeling requirements for intravenous and subcutaneous immune globulin products.
Regulatory teams should ensure all product labeling, promotional materials, and medical information inquiries align with these three primary indications. QA and Pharmacovigilance should monitor for adverse events specifically within these patient populations as part of routine surveillance.
For use in primary humoral immunodeficiency, idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Open in openFDA / FDA.gov